ArticleFrontiers in oncology2026
FAT2 inhibits breast cancer cell migration, invasion, and epithelial-mesenchymal transition through transcriptional upregulation of CLDN19.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: FAT atypical cadherin 2 (FAT2), a member of the protocadherin superfamily involved in cell adhesion and polarity, remains incompletely characterized in breast cancer. This study aimed to elucidate the expression pattern, clinical significance, and functional mechanisms of FAT2 in breast cancer. Methods: FAT2 expression and clinicopathological associations were analyzed using The Cancer Genome Atlas (TCGA) dataset. Recombinant FAT2 protein was generated, and its effects on migration, invasion, and epithelial-mesenchymal transition (EMT) were assessed in HER2-positive breast cancer cell lines (BT-474 and MDA-MB-453). Downstream effectors were identified through gene set enrichment analysis (GSEA) combined with correlation analysis and validated by gain- and loss-of-function experiments. Immunohistochemical analysis of 31 paired clinical specimens was performed to corroborate the Results: FAT2 mRNA was significantly downregulated in breast cancer tissues and was associated with advanced clinical stage, higher T stage, and negative hormone receptor status. High FAT2 expression correlated with longer overall survival, particularly in the ER-positive subgroup. Functionally, recombinant FAT2 protein inhibited cell migration and invasion at sub-cytotoxic concentrations and reversed the EMT phenotype. Integrative bioinformatics analysis identified the tight junction protein CLDN19 as a key downstream effector of FAT2, and rescue experiments demonstrated that CLDN19 knockdown markedly attenuated FAT2-mediated anti-migratory and anti-EMT effects. Immunohistochemical analysis validated the concurrent downregulation and strong positive correlation of FAT2 and CLDN19 in clinical specimens. Conclusions: FAT2 functions as a tumor suppressor in breast cancer by inhibiting migration, invasion, and EMT through transcriptional upregulation of CLDN19. The FAT2-CLDN19 axis represents a potential prognostic biomarker and therapeutic target for anti-metastatic intervention in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.